12:00 AM
 | 
Aug 29, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Adcetris brentuximab vedotin: Phase II started

Seattle Genetics began an open-label, U.S. Phase II trial to evaluate 1.8 mg/kg IV Adcetris brentuximab vedotin every 3 weeks in about 55 patients with relapsed or refractory CD30-positive NHL, including diffuse large B cell lymphoma, peripheral T cell lymphoma (PTCL) and other less common lymphoma subtypes.

Read the full 220 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >